Search results
Results From The WOW.Com Content Network
It was established in 2002 [1] and covers drug discovery and development. The editor-in-chief is Peter Kirkpatrick. [ 2 ] According to the Journal Citation Reports , the journal has a 2021 impact factor of 112.288, ranking it 1st out of 158 journals in the category "Biotechnology & Applied Microbiology" [ 3 ] and 1st out of 279 journals in the ...
Forward (classical) and reverse pharmacology approaches in drug discovery. In the field of drug discovery, classical pharmacology, [1] also known as forward pharmacology, [2] [3] [4] or phenotypic drug discovery (PDD), [5] relies on phenotypic screening (screening in intact cells or whole organisms) of chemical libraries of synthetic small molecules, natural products or extracts to identify ...
High-throughput screening (HTS) is a method for scientific discovery especially used in drug discovery and relevant to the fields of biology, materials science [1] and chemistry. [ 2 ] [ 3 ] Using robotics , data processing/control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to ...
The Nature Partner Journals series, abbreviated npj, is a series of online-only, open access, journals. It was launched in April 2014 with three journals: npj Primary Care Respiratory Medicine , npj Biofilms and Microbiomes , and npj Schizophrenia .
Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015 Jan;14(1):58-74. PubMed PMID 25549588. Lokireddy, S, Kukushkin, NV, and Goldberg, AL. cAMP-induced phosphorylation of the 26S proteasome enhances its function and the degradation of misfolded proteins.
The woman was a part of a clinical trial involving 19 children that took place from 2004 to 2009, researchers wrote in Nature. For the trial, ...
A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye ...
Min Zhuo. Min Zhuo (born 1964) is a pain neuroscientist at the University of Toronto in Canada. [1] He is the Michael Smith Chair in Neuroscience and Mental Health as well as the Canada Research Chair in Pain and Cognition and a Fellow of the Royal Society of Canada.